<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604175</url>
  </required_header>
  <id_info>
    <org_study_id>A5240</org_study_id>
    <secondary_id>10393</secondary_id>
    <secondary_id>ACTG A5240</secondary_id>
    <nct_id>NCT00604175</nct_id>
  </id_info>
  <brief_title>Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women</brief_title>
  <official_title>A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human papillomavirus (HPV) is the most common sexually transmitted disease in the world. HPV
      infection can cause genital warts and certain cervical problems, including cervical cancer.
      HPV infection may be more severe and harder to treat in HIV-infected people. The purpose of
      this study was to determine whether the quadrivalent HPV vaccine is safe, tolerable, and
      effective in producing antibodies to HPV in HIV-infected women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HPV is a DNA virus that affects both men and women. Approximately 90 types of HPV have been
      identified, 30 of which are sexually transmitted. The most common forms of HPV are types 6,
      11, 16, and 18. The quadrivalent HPV vaccine that was tested in this study had been shown in
      previous studies to be effective in preventing infection with HPV 6, 11, 16, and 18 in
      healthy young women. According to a report by the Centers for Disease Control and Prevention
      (CDC), 80% of women will have acquired HPV by the age of 50. HIV infected women have been
      reported to have a higher prevalence and persistence of HPV infection, as well as an
      increased risk for abnormal Pap smears and cervical cancer. HPV types 16 and 18 cause the
      majority of cervical cancers worldwide, and types 6 and 11 are responsible for the majority
      of cases of genital warts. Vaccinations for preventable infections are particularly important
      among HIV infected people because people with HIV have compromised immune systems; therefore,
      any infection is very serious and can potentially be fatal. However, standard vaccination
      series have not been very successful because a compromised immune system may not produce the
      desired immune response to a vaccine. The HPV vaccine is designed to protect against
      infection with HPV types 6, 11, 16, and 18 and has been approved by the FDA for use in women
      between the ages of 9 and 26. The purpose of this study was to determine whether the
      quadrivalent HPV vaccine is safe, tolerable, and effective in producing antibodies to HPV in
      HIV infected females.

      The study consisted of single arm evaluations of HPV vaccine immunogenicity and safety in 3
      groups based on the study screening CD4 cell count as follows:

        -  Stratum A: CD4 cell count &gt;350 cells/mm^3

        -  Stratum B: CD4 cell count &gt;200 to &lt;=350 cells/mm^3

        -  Stratum C: CD4 cell count &lt;=200 cells/mm^3

      In Version 1.0 of the protocol, the target accrual was n=67 participants with screening HIV
      viral load &lt;=10,000 copies/mL and n=67 participants with HIV viral load &gt;10,000 copies/mL
      within each CD4 stratum, yielding n=134 in each CD4 stratum. In light of subsequent findings
      from completed HPV vaccine studies, the sample size was changed to n=94 participants per CD4
      stratum in Version 2.0 of the protocol, and stratification by screening HIV viral load was
      removed. All Stratum A and Stratum B participants were enrolled under protocol Version 1.0.

      The study duration was 72 weeks. All participants received HPV vaccine administered by
      intramuscular injection at baseline, and at Weeks 8 and 24. Following each injection,
      participants remained at the clinic for 30 minutes of observation for adverse events. A
      telephone follow-up or a home visit by study staff was performed within 2 days following each
      injection.

      Participants returned to the clinic for visits at Weeks 4, 8, 12, 24, 28, 52, and 72. Most
      study visits included a physical exam, medication review, blood and urine collection, and
      answering questions about signs and symptoms since previous visit. Some visits included
      measurement of HIV viral load and CD4 cell count; collection of endocervical wick, cervical
      cytobrush and anal swab; and an oral exam. A subset of participants were asked to provide
      additional blood samples and oral cytobrush specimens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series</measure>
    <time_frame>Week 28</time_frame>
    <description>Percentage of participants with HPV6 antibody development from seronegative status (HPV6 antibody titers &lt;20 mMU/mL) at baseline to seropositive (HPV6 antibody titers &gt;=20 mMU/mL) status a month after the completion of HPV vaccination series. HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With HPV11 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series</measure>
    <time_frame>Week 28</time_frame>
    <description>Percentage of participants with HPV11 antibody development from seronegative status (HPV11 antibody titers &lt;16 mMU/mL) at baseline to seropositive (HPV11 antibody titers &gt;=16 mMU/mL) status a month after the completion of HPV vaccination series. HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With HPV16 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series</measure>
    <time_frame>Week 28</time_frame>
    <description>Percentage of participants with HPV16 antibody development from seronegative status (HPV16 antibody titers &lt;20 mMU/mL) at baseline to seropositive (HPV16 antibody titers &gt;=20 mMU/mL) status a month after the completion of HPV vaccination series. HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With HPV18 Antibody Development From the Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series</measure>
    <time_frame>Week 28</time_frame>
    <description>Percentage of participants with HPV18 antibody development from seronegative status (HPV18 antibody titers &lt;24 mMU/mL) at baseline to seropositive (HPV18 antibody titers &gt;=24 mMU/mL) status a month after the completion of HPV vaccination series. HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HPV6 Antibody Titers Among Those Seronegative for HPV6 at Baseline</measure>
    <time_frame>Weeks 28, 72</time_frame>
    <description>HPV antibody titers to type 6 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (7 mMU/mL, and after assay change in December 2012, 11 mMU/mL for HPV6). Geometric mean HPV6 titers with 95% CIs were calculated among the subset of participants who were seronegative for HPV6 (&lt;20 mMU/mL) at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV11 Antibody Titers Among Those Seronegative for HPV11 at Baseline</measure>
    <time_frame>Weeks 28, 72</time_frame>
    <description>HPV antibody titers to type 11 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (8 mMU/mL for HPV11). Geometric mean HPV11 titers with 95% CIs were calculated among the subset of participants who were seronegative for HPV11 (&lt;16 mMU/mL) at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV16 Antibody Titers Among Those Seronegative for HPV16 at Baseline</measure>
    <time_frame>Weeks 28, 72</time_frame>
    <description>HPV antibody titers to type 16 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (11 mMU/mL for HPV16). Geometric mean HPV16 titers with 95% CIs were calculated among the subset of participants who were seronegative for HPV16 (&lt;20 mMU/mL) at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV18 Antibody Titers Among Those Seronegative for HPV18 at Baseline</measure>
    <time_frame>Weeks 28, 72</time_frame>
    <description>HPV antibody titers to type 18 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (10 mMU/mL for HPV18). Geometric mean HPV18 titers with 95% CIs were calculated among the subset of participants who were seronegative for HPV18 (&lt;24 mMU/mL) at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Log10 HPV6 Antibody Titers From Baseline Among Those Seropositive for HPV6 at Baseline</measure>
    <time_frame>Weeks 0, 28, 72</time_frame>
    <description>Change in log10 HPV6 antibody titers was calculated as log10 HPV6 antibody titers at a later timepoint (Week 28, Week 72) minus log10 HPV6 antibody titers at baseline among those seropositive for HPV6 (&gt;=20 mMU/mL) at baseline. HPV antibody titers to type 6 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (7 mMU/mL, and after assay change in December 2012, 11 mMU/mL for HPV6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Log10 HPV11 Antibody Titers From Baseline Among Those Seropositive for HPV11 at Baseline</measure>
    <time_frame>Weeks 0, 28, 72</time_frame>
    <description>Change in log10 HPV11 antibody titers was calculated as log10 HPV11 antibody titers at a later timepoint (Week 28, Week 72) minus log10 HPV11 antibody titers at baseline among those seropositive for HPV11 (&gt;=16 mMU/mL) at baseline. HPV antibody titers to type 11 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (8 mMU/mL for HPV11).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Log10 HPV16 Antibody Titers From Baseline Among Those Seropositive for HPV16 at Baseline</measure>
    <time_frame>Weeks 0, 28, 72</time_frame>
    <description>Change in log10 HPV16 antibody titers was calculated as log10 HPV16 antibody titers at a later timepoint (Week 28, Week 72) minus log10 HPV16 antibody titers at baseline among those seropositive for HPV16 (&gt;=20 mMU/mL) at baseline. HPV antibody titers to type 16 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (11 mMU/mL for HPV16).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Log10 HPV18 Antibody Titers From Baseline Among Those Seropositive for HPV18 at Baseline</measure>
    <time_frame>Weeks 0, 28, 72</time_frame>
    <description>Change in log10 HPV18 antibody titers was calculated as log10 HPV18 antibody titers at a later timepoint (Week 28, Week 72) minus log10 HPV18 antibody titers at baseline among those seropositive for HPV18 (&gt;=24 mMU/mL) at baseline. HPV antibody titers to type 18 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (10 mMU/mL for HPV18).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Signs and Symptoms of Grade 3 or Higher</measure>
    <time_frame>From baseline to up to Week 72</time_frame>
    <description>Number of participants who experienced a sign or symptom of Grade 3 or higher at any time after baseline while on study. Grading of signs and symptoms was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities of Grade 3 or Higher</measure>
    <time_frame>From baseline to up to Week 72</time_frame>
    <description>Number of participants who experienced a laboratory abnormality of Grade 3 or higher at any time after baseline while on study. Grading of laboratory abnormalities was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Log10 HIV Viral Load (VL) From Baseline</measure>
    <time_frame>Weeks 0, 4, 12, 28, 52, and 72</time_frame>
    <description>A blood sample was drawn for local testing to determine the HIV VL. Change in log10 HIV VL was calculated as log10 HIV VL at a later time point (Weeks 4, 12, 28, 52 and 72) minus log10 HIV VL at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 Cell Count From Baseline</measure>
    <time_frame>Weeks 0, 4, 8, 12, 24, 28, 52 and 72</time_frame>
    <description>A blood sample was drawn for local testing to determine the CD4 cell count. Change in CD4 cell count was calculated as CD4 cell count at a later time point (Weeks 4, 8, 12, 24, 28, 52 and 72) minus CD4 cell count at baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">319</enrollment>
  <condition>HIV Infections</condition>
  <condition>Sexually Transmitted Diseases</condition>
  <arm_group>
    <arm_group_label>Stratum A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with screening CD4 count &gt;350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with screening CD4 count &gt;200 to &lt;=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with screening CD4 count &lt;=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent HPV vaccine</intervention_name>
    <description>Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.</description>
    <arm_group_label>Stratum A</arm_group_label>
    <arm_group_label>Stratum B</arm_group_label>
    <arm_group_label>Stratum C</arm_group_label>
    <other_name>GARDASIL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection

          -  CD4 count obtained within 45 days prior to study entry

          -  Karnofsky performance score &gt;=70 on at least one occasion within 45 days prior to
             study entry

          -  The following labs within 45 days prior to study entry:

               -  hemoglobin &gt;8.0 g/dL

               -  direct bilirubin &lt;2.5 x upper limit of normal (ULN)

               -  alanine aminotransferase, ALT (SGPT) &lt;3 xULN

               -  aspartate aminotransferase, AST (SGOT) &lt;3 xULN

               -  platelet count &gt;=100,000 /mm^3

          -  Willing to use acceptable forms of contraception for the duration of the study

          -  Written informed consent from participant or from parent or guardian, if applicable

          -  If on HAART, then the same regimen for at least 12 weeks prior to study entry with no
             change within 30 days prior to study entry. (This criterion was removed in Version 2.0
             of the protocol.)

          -  HIV viral load obtained within 45 days prior to study entry (This criterion was
             removed in Version 2.0 of the protocol.)

        Exclusion Criteria:

          -  Abnormal Pap test with confirmed biopsy results of cervical intraepithelial neoplasia
             (CIN) II or III or cervical cancer within 180 days prior to study entry

          -  Vulval intraepithelial neoplasia (VIN) II or III or cancer confirmed by biopsy results
             within 180 days prior to study entry

          -  Physician-diagnosed genital warts within 180 days prior to study entry

          -  Previous cervical dysplasia treatment, including loop electrosurgical excision
             procedure (LEEP), cervical cryotherapy, cone biopsy, and cervical laser vaporization
             within 180 days prior to study entry

          -  Use of any systemic antineoplastic or immunomodulatory treatment, systemic
             corticosteroids, investigational vaccines, interleukins, interferons, growth factors,
             or intravenous immunoglobulin (IVIG) within 45 days prior to study entry. Participants
             who had received standard of care (e.g., hepatitis B, influenza, and tetanus) vaccines
             were not excluded.

          -  Known allergy or hypersensitivity to yeast or any components of the vaccine or its
             formulation

          -  Current drug or alcohol use or dependence or any other condition that may interfere
             with study participation

          -  Serious illness requiring systemic treatment and/or hospitalization within 45 days
             prior to study entry

          -  Total hysterectomy. Participants who had undergone partial hysterectomy and had a
             cervix were not excluded.

          -  Hemophilia

          -  Currently on anticoagulation therapy other than acetylsalicylic acid

          -  Prior vaccination with an HPV vaccine

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erna Milunka Kojic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Immunology/Infectious Disease, The Miriam Hospital, Brown University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Cu-Uvin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Obstetrics-Gynecology and Medicine, The Miriam Hospital, Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-2050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Usc La Nichd Crs</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, UC San Diego CRS</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0672</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller Children's Hosp. Long Beach CA NICHD CRS</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-1079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford AIDS Clinical Trials Unit CRS</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-5350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Hiv/Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Public Health CRS</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University CRS (GU CRS)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Univ. Washington DC NICHD CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida CDTC Ft Lauderdale NICHD CRS</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Florida Jacksonville NICHD CRS</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Perinatal HIV Clinical Trials Unit CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Miami AIDS Clinical Research Unit (ACRU) CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens &amp; Childrens HIV Program</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ. New Orleans NICHD CRS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHV Baltimore Treatment CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital CRS (MGH CRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bmc Actg Crs</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Med. Ctr., ACTG CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hosp. CRS</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Therapeutics (WT) CRS</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Univ. Hosp. CRS</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School- Adult Clinical Research Ctr. CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Chelsea CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia P&amp;S CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia IMPAACT CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Hill CRS</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ. Med. Ctr. Adult CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greensboro CRS</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research &amp; Education Group-Portland CRS</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Therapeutics, CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson Univ. Med. Ctr. CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital Clinical Research Site (TMH CRS) CRS</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics (VT) CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Health and Wellness Center CRS</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston AIDS Research Team CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth Univ. Medical Ctr. CRS</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-9929</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico AIDS Clinical Trials Unit CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico Pediatric HIV/AIDS Research Program CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Helen Joseph Hospital CRS (Wits HJH CRS)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cameron JE, Hagensee ME. Human papillomavirus infection and disease in the HIV+ individual. Cancer Treat Res. 2007;133:185-213. Review.</citation>
    <PMID>17672042</PMID>
  </reference>
  <reference>
    <citation>Chaturvedi AK, Goedert JJ. Human papillomavirus genotypes among women with HIV: implications for research and prevention. AIDS. 2006 Nov 28;20(18):2381-3.</citation>
    <PMID>17117025</PMID>
  </reference>
  <reference>
    <citation>De Vuyst H, Franceschi S. Human papillomavirus vaccines in HIV-positive men and women. Curr Opin Oncol. 2007 Sep;19(5):470-5. Review.</citation>
    <PMID>17762573</PMID>
  </reference>
  <reference>
    <citation>Kojic EM, Cu-Uvin S. Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. Curr Opin Oncol. 2007 Sep;19(5):464-9. Review.</citation>
    <PMID>17762572</PMID>
  </reference>
  <reference>
    <citation>Palefsky J. Human papillomavirus infection in HIV-infected persons. Top HIV Med. 2007 Aug-Sep;15(4):130-3. Review.</citation>
    <PMID>17720998</PMID>
  </reference>
  <results_reference>
    <citation>Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C, Grinsztejn B, Palefsky JM, Webster-Cyriaque JY, Saah A, Aberg JA, Cu-Uvin S. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014 Jul 1;59(1):127-35. doi: 10.1093/cid/ciu238. Epub 2014 Apr 9.</citation>
    <PMID>24723284</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <results_first_submitted>July 15, 2013</results_first_submitted>
  <results_first_submitted_qc>August 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 17, 2013</results_first_posted>
  <disposition_first_submitted>December 11, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>December 28, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 1, 2013</disposition_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HPV 6</keyword>
  <keyword>HPV 11</keyword>
  <keyword>HPV 16</keyword>
  <keyword>HPV 18</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>319 HIV-infected women 13-45 years of age were recruited in US, South Africa and Brazil between March 2008 and July 2011 for participation in this study.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into 3 strata based on screening CD4 cell count:
Stratum A: CD4 cell count &gt;350 cells/mm^3
Stratum B: CD4 cell count &gt;200 to &lt;=350 cells/mm^3
Stratum C: CD4 cell count &lt;=200 cells/mm^3</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Stratum A</title>
          <description>Participants with screening CD4 count &gt;350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
        </group>
        <group group_id="P2">
          <title>Stratum B</title>
          <description>Participants with screening CD4 count &gt;200 to &lt;=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
        </group>
        <group group_id="P3">
          <title>Stratum C</title>
          <description>Participants with screening CD4 count &lt;=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Entry Through Week 28</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120">Completed 28 weeks of the study (the primary endpoint time point).</participants>
                <participants group_id="P2" count="92">Completed 28 weeks of the study (the primary endpoint time point).</participants>
                <participants group_id="P3" count="93">Completed 28 weeks of the study (the primary endpoint time point).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not start intervention</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 29 Through Week 72</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-adherence to study requirements</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants, except 4: one was found to be ineligible after enrollment (Stratum A) and 3 failed to start intervention (2 in Stratum A, 1 in Stratum C).</population>
      <group_list>
        <group group_id="B1">
          <title>Stratum A</title>
          <description>Participants with screening CD4 count &gt;350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
        </group>
        <group group_id="B2">
          <title>Stratum B</title>
          <description>Participants with screening CD4 count &gt;200 to &lt;=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
        </group>
        <group group_id="B3">
          <title>Stratum C</title>
          <description>Participants with screening CD4 count &lt;=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="93"/>
            <count group_id="B4" value="315"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="29" upper_limit="40"/>
                    <measurement group_id="B2" value="38" lower_limit="33" upper_limit="42"/>
                    <measurement group_id="B3" value="36" lower_limit="31" upper_limit="40"/>
                    <measurement group_id="B4" value="36" lower_limit="30" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>13 - 17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 - 24 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 - 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 - 34 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35 - 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 - 45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race/ethnicity, self-reported (NIH categories).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White, Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black, Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (Regardless of Race)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian, Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV Antiretroviral Therapy (ART) Status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>On ART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not on ART</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Cell Count</title>
          <units>Cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="519" lower_limit="418" upper_limit="664"/>
                    <measurement group_id="B2" value="287" lower_limit="246" upper_limit="344"/>
                    <measurement group_id="B3" value="154" lower_limit="86" upper_limit="188"/>
                    <measurement group_id="B4" value="310" lower_limit="197" upper_limit="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nadir CD4 Cell Count</title>
          <units>Cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="368" lower_limit="234" upper_limit="482"/>
                    <measurement group_id="B2" value="176" lower_limit="64" upper_limit="261"/>
                    <measurement group_id="B3" value="41" lower_limit="20" upper_limit="108"/>
                    <measurement group_id="B4" value="179" lower_limit="47" upper_limit="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV Viral Load</title>
          <description>A blood sample was drawn for HIV viral load testing by local laboratories. The assays used were Roche Amplicor Monitor HIV RT PCR, Roche UltraSensitive HIV RT PCR, bDNA (Versant HIV-1 RNA 3.0, 3rd), Roche COBAS AmpliPrep/Taqman HIV and Abbott RealTime HIV-1.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=10,000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10,000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human Papillomavirus Type 6 (HPV6) Serostatus</title>
          <description>HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. Seronegative status was defined as HPV6 antibody titers &lt;20 mMU/mL and seropositive as HPV6 antibody titers &gt;=20 mMU/mL.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Seronegative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human Papillomavirus Type 11 (HPV11) Serostatus</title>
          <description>HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. Seronegative status was defined as HPV11 antibody titers &lt;16 mMU/mL and seropositive as HPV11 antibody titers &gt;=16 mMU/mL.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Seronegative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human Papillomavirus Type 16 (HPV16) Serostatus</title>
          <description>HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. Seronegative status was defined as HPV16 antibody titers &lt;20 mMU/mL and seropositive as HPV16 antibody titers &gt;=20 mMU/mL.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Seronegative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human Papillomavirus Type 18 (HPV18) Serostatus</title>
          <description>HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. Seronegative status was defined as HPV18 antibody titers &lt;24 mMU/mL and seropositive as HPV18 antibody titers &gt;=24 mMU/mL.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Seronegative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series</title>
        <description>Percentage of participants with HPV6 antibody development from seronegative status (HPV6 antibody titers &lt;20 mMU/mL) at baseline to seropositive (HPV6 antibody titers &gt;=20 mMU/mL) status a month after the completion of HPV vaccination series. HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum.</description>
        <time_frame>Week 28</time_frame>
        <population>Per-protocol analysis including all participants seronegative to HPV6 at baseline who completed the vaccination series per protocol and had HPV6 titer available at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A</title>
            <description>Participants with screening CD4 count &gt;350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B</title>
            <description>Participants with screening CD4 count &gt;200 to &lt;=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C</title>
            <description>Participants with screening CD4 count &lt;=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series</title>
          <description>Percentage of participants with HPV6 antibody development from seronegative status (HPV6 antibody titers &lt;20 mMU/mL) at baseline to seropositive (HPV6 antibody titers &gt;=20 mMU/mL) status a month after the completion of HPV vaccination series. HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum.</description>
          <population>Per-protocol analysis including all participants seronegative to HPV6 at baseline who completed the vaccination series per protocol and had HPV6 titer available at Week 28.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="87.3" upper_limit="99.5"/>
                    <measurement group_id="O2" value="100.0" lower_limit="92.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="84.4" lower_limit="70.5" upper_limit="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HPV11 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series</title>
        <description>Percentage of participants with HPV11 antibody development from seronegative status (HPV11 antibody titers &lt;16 mMU/mL) at baseline to seropositive (HPV11 antibody titers &gt;=16 mMU/mL) status a month after the completion of HPV vaccination series. HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum.</description>
        <time_frame>Week 28</time_frame>
        <population>Per-protocol analysis including all participants seronegative to HPV11 at baseline who completed the vaccination series per protocol and had HPV11 titer available at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A</title>
            <description>Participants with screening CD4 count &gt;350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B</title>
            <description>Participants with screening CD4 count &gt;200 to &lt;=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C</title>
            <description>Participants with screening CD4 count &lt;=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HPV11 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series</title>
          <description>Percentage of participants with HPV11 antibody development from seronegative status (HPV11 antibody titers &lt;16 mMU/mL) at baseline to seropositive (HPV11 antibody titers &gt;=16 mMU/mL) status a month after the completion of HPV vaccination series. HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum.</description>
          <population>Per-protocol analysis including all participants seronegative to HPV11 at baseline who completed the vaccination series per protocol and had HPV11 titer available at Week 28.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="91.9" upper_limit="99.7"/>
                    <measurement group_id="O2" value="98.3" lower_limit="90.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="91.9" lower_limit="82.2" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HPV16 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series</title>
        <description>Percentage of participants with HPV16 antibody development from seronegative status (HPV16 antibody titers &lt;20 mMU/mL) at baseline to seropositive (HPV16 antibody titers &gt;=20 mMU/mL) status a month after the completion of HPV vaccination series. HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum.</description>
        <time_frame>Week 28</time_frame>
        <population>Per-protocol analysis including all participants seronegative to HPV16 at baseline who completed the vaccination series per protocol and had HPV16 titer available at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A</title>
            <description>Participants with screening CD4 count &gt;350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B</title>
            <description>Participants with screening CD4 count &gt;200 to &lt;=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C</title>
            <description>Participants with screening CD4 count &lt;=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HPV16 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series</title>
          <description>Percentage of participants with HPV16 antibody development from seronegative status (HPV16 antibody titers &lt;20 mMU/mL) at baseline to seropositive (HPV16 antibody titers &gt;=20 mMU/mL) status a month after the completion of HPV vaccination series. HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum.</description>
          <population>Per-protocol analysis including all participants seronegative to HPV16 at baseline who completed the vaccination series per protocol and had HPV16 titer available at Week 28.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="92.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.2" lower_limit="90.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="92.9" lower_limit="82.7" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HPV18 Antibody Development From the Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series</title>
        <description>Percentage of participants with HPV18 antibody development from seronegative status (HPV18 antibody titers &lt;24 mMU/mL) at baseline to seropositive (HPV18 antibody titers &gt;=24 mMU/mL) status a month after the completion of HPV vaccination series. HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum.</description>
        <time_frame>Week 28</time_frame>
        <population>Per-protocol analysis including all participants seronegative to HPV18 at baseline who completed the vaccination series per protocol and had HPV18 titer available at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A</title>
            <description>Participants with screening CD4 count &gt;350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B</title>
            <description>Participants with screening CD4 count &gt;200 to &lt;=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C</title>
            <description>Participants with screening CD4 count &lt;=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HPV18 Antibody Development From the Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series</title>
          <description>Percentage of participants with HPV18 antibody development from seronegative status (HPV18 antibody titers &lt;24 mMU/mL) at baseline to seropositive (HPV18 antibody titers &gt;=24 mMU/mL) status a month after the completion of HPV vaccination series. HPV serotyping was performed centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum.</description>
          <population>Per-protocol analysis including all participants seronegative to HPV18 at baseline who completed the vaccination series per protocol and had HPV18 titer available at Week 28.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0" lower_limit="82.4" upper_limit="96.3"/>
                    <measurement group_id="O2" value="84.5" lower_limit="74.0" upper_limit="92.0"/>
                    <measurement group_id="O3" value="75.4" lower_limit="62.7" upper_limit="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPV6 Antibody Titers Among Those Seronegative for HPV6 at Baseline</title>
        <description>HPV antibody titers to type 6 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (7 mMU/mL, and after assay change in December 2012, 11 mMU/mL for HPV6). Geometric mean HPV6 titers with 95% CIs were calculated among the subset of participants who were seronegative for HPV6 (&lt;20 mMU/mL) at baseline.</description>
        <time_frame>Weeks 28, 72</time_frame>
        <population>All eligible participants who received at least one vaccine and were seronegative for HPV6 (HPV6-) at baseline (the number of participants analyzed) and had HPV6 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=60; 58; 52. Week 72: n=55; 53; 53.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A/Baseline HPV6-</title>
            <description>Participants with screening CD4+ count &gt;350 cells/mm^3 (Stratum A) who were seronegative for HPV6 at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B/Baseline HPV6-</title>
            <description>Participants with screening CD4+ count &gt;200 to &lt;=350 cells/mm^3 (Stratum B) who were seronegative for HPV6 at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C/Baseline HPV6-</title>
            <description>Participants with screening CD4+ count&lt;=200 cells/mm^3 (Stratum C) who were seronegative for HPV6 at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>HPV6 Antibody Titers Among Those Seronegative for HPV6 at Baseline</title>
          <description>HPV antibody titers to type 6 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (7 mMU/mL, and after assay change in December 2012, 11 mMU/mL for HPV6). Geometric mean HPV6 titers with 95% CIs were calculated among the subset of participants who were seronegative for HPV6 (&lt;20 mMU/mL) at baseline.</description>
          <population>All eligible participants who received at least one vaccine and were seronegative for HPV6 (HPV6-) at baseline (the number of participants analyzed) and had HPV6 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=60; 58; 52. Week 72: n=55; 53; 53.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV6 titers at Week 28 (n=60; 58; 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462.3" lower_limit="320.5" upper_limit="666.8"/>
                    <measurement group_id="O2" value="349.2" lower_limit="242.1" upper_limit="503.8"/>
                    <measurement group_id="O3" value="137.1" lower_limit="82.0" upper_limit="229.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV6 titers at Week 72 (n=55; 53; 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.8" lower_limit="81.5" upper_limit="155.9"/>
                    <measurement group_id="O2" value="79.9" lower_limit="52.1" upper_limit="122.6"/>
                    <measurement group_id="O3" value="43.0" lower_limit="29.0" upper_limit="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPV11 Antibody Titers Among Those Seronegative for HPV11 at Baseline</title>
        <description>HPV antibody titers to type 11 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (8 mMU/mL for HPV11). Geometric mean HPV11 titers with 95% CIs were calculated among the subset of participants who were seronegative for HPV11 (&lt;16 mMU/mL) at baseline.</description>
        <time_frame>Weeks 28, 72</time_frame>
        <population>All eligible participants who received at least one vaccine and were seronegative for HPV11 (HPV11-) at baseline (the number of participants analyzed) and had HPV11 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=93; 70; 71. Week 72: n=83; 66; 69.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A/Baseline HPV11-</title>
            <description>Participants with screening CD4+ count &gt;350 cells/mm^3 (Stratum A) who were seronegative for HPV11 at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B/Baseline HPV11-</title>
            <description>Participants with screening CD4+ count &gt;200 to &lt;=350 cells/mm^3 (Stratum B) who were seronegative for HPV11 at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C/Baseline HPV11-</title>
            <description>Participants with screening CD4+ count&lt;=200 cells/mm^3 (Stratum C) who were seronegative for HPV11 at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>HPV11 Antibody Titers Among Those Seronegative for HPV11 at Baseline</title>
          <description>HPV antibody titers to type 11 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (8 mMU/mL for HPV11). Geometric mean HPV11 titers with 95% CIs were calculated among the subset of participants who were seronegative for HPV11 (&lt;16 mMU/mL) at baseline.</description>
          <population>All eligible participants who received at least one vaccine and were seronegative for HPV11 (HPV11-) at baseline (the number of participants analyzed) and had HPV11 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=93; 70; 71. Week 72: n=83; 66; 69.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV11 at Week 28 (n=93; 70; 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476.5" lower_limit="361.8" upper_limit="627.5"/>
                    <measurement group_id="O2" value="417.2" lower_limit="286.8" upper_limit="606.8"/>
                    <measurement group_id="O3" value="205.1" lower_limit="128.7" upper_limit="326.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV11 at Week 72 (n=83; 66; 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.3" lower_limit="90.1" upper_limit="166.0"/>
                    <measurement group_id="O2" value="85.1" lower_limit="56.0" upper_limit="129.3"/>
                    <measurement group_id="O3" value="52.9" lower_limit="35.0" upper_limit="79.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPV16 Antibody Titers Among Those Seronegative for HPV16 at Baseline</title>
        <description>HPV antibody titers to type 16 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (11 mMU/mL for HPV16). Geometric mean HPV16 titers with 95% CIs were calculated among the subset of participants who were seronegative for HPV16 (&lt;20 mMU/mL) at baseline.</description>
        <time_frame>Weeks 28, 72</time_frame>
        <population>All eligible participants who received at least one vaccine and were seronegative for HPV16 (HPV16-) at baseline (the number of participants analyzed) and had HPV16 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=73; 63; 64. Week 72: n=63; 59; 64.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A/Baseline HPV16-</title>
            <description>Participants with screening CD4+ count &gt;350 cells/mm^3 (Stratum A) who were seronegative for HPV16 at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B/Baseline HPV16-</title>
            <description>Participants with screening CD4+ count &gt;200 to &lt;=350 cells/mm^3 (Stratum B) who were seronegative for HPV16 at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C/Baseline HPV16-</title>
            <description>Participants with screening CD4+ count&lt;=200 cells/mm^3 (Stratum C) who were seronegative for HPV16 at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>HPV16 Antibody Titers Among Those Seronegative for HPV16 at Baseline</title>
          <description>HPV antibody titers to type 16 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (11 mMU/mL for HPV16). Geometric mean HPV16 titers with 95% CIs were calculated among the subset of participants who were seronegative for HPV16 (&lt;20 mMU/mL) at baseline.</description>
          <population>All eligible participants who received at least one vaccine and were seronegative for HPV16 (HPV16-) at baseline (the number of participants analyzed) and had HPV16 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=73; 63; 64. Week 72: n=63; 59; 64.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV16 at Week 28 (n=73; 63; 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1199.9" lower_limit="870.5" upper_limit="1654.1"/>
                    <measurement group_id="O2" value="1117.1" lower_limit="746.2" upper_limit="1672.4"/>
                    <measurement group_id="O3" value="570.8" lower_limit="327.7" upper_limit="994.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV16 at Week 72 (n=63; 59; 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.9" lower_limit="171.3" upper_limit="361.6"/>
                    <measurement group_id="O2" value="170.4" lower_limit="106.8" upper_limit="271.8"/>
                    <measurement group_id="O3" value="98.3" lower_limit="61.9" upper_limit="156.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPV18 Antibody Titers Among Those Seronegative for HPV18 at Baseline</title>
        <description>HPV antibody titers to type 18 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (10 mMU/mL for HPV18). Geometric mean HPV18 titers with 95% CIs were calculated among the subset of participants who were seronegative for HPV18 (&lt;24 mMU/mL) at baseline.</description>
        <time_frame>Weeks 28, 72</time_frame>
        <population>All eligible participants who received at least one vaccine and were seronegative for HPV18 (HPV18-) at baseline (the number of participants analyzed) and had HPV18 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=86; 80; 69. Week 72: n=75; 73; 69.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A/Baseline HPV18-</title>
            <description>Participants with screening CD4+ count &gt;350 cells/mm^3 (Stratum A) who were seronegative for HPV18 at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B/Baseline HPV18-</title>
            <description>Participants with screening CD4+ count &gt;200 to &lt;=350 cells/mm^3 (Stratum B) who were seronegative for HPV18 at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C/Baseline HPV18-</title>
            <description>Participants with screening CD4+ count&lt;=200 cells/mm^3 (Stratum C) who were seronegative for HPV18 at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>HPV18 Antibody Titers Among Those Seronegative for HPV18 at Baseline</title>
          <description>HPV antibody titers to type 18 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (10 mMU/mL for HPV18). Geometric mean HPV18 titers with 95% CIs were calculated among the subset of participants who were seronegative for HPV18 (&lt;24 mMU/mL) at baseline.</description>
          <population>All eligible participants who received at least one vaccine and were seronegative for HPV18 (HPV18-) at baseline (the number of participants analyzed) and had HPV18 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=86; 80; 69. Week 72: n=75; 73; 69.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV18 at Week 28 (n=86; 80; 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.0" lower_limit="126.2" upper_limit="242.6"/>
                    <measurement group_id="O2" value="170.8" lower_limit="114.5" upper_limit="254.7"/>
                    <measurement group_id="O3" value="93.6" lower_limit="58.6" upper_limit="149.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV18 at Week 72 (n=75; 73; 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9" lower_limit="29.5" upper_limit="59.0"/>
                    <measurement group_id="O2" value="40.6" lower_limit="27.0" upper_limit="61.2"/>
                    <measurement group_id="O3" value="20.8" lower_limit="14.5" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Log10 HPV6 Antibody Titers From Baseline Among Those Seropositive for HPV6 at Baseline</title>
        <description>Change in log10 HPV6 antibody titers was calculated as log10 HPV6 antibody titers at a later timepoint (Week 28, Week 72) minus log10 HPV6 antibody titers at baseline among those seropositive for HPV6 (&gt;=20 mMU/mL) at baseline. HPV antibody titers to type 6 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (7 mMU/mL, and after assay change in December 2012, 11 mMU/mL for HPV6).</description>
        <time_frame>Weeks 0, 28, 72</time_frame>
        <population>All eligible participants who received at least one vaccine and were seropositive for HPV6 (HPV6+) at baseline (the number of participants analyzed) and had HPV6 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=52; n=33; n=36. Week 72: n=43; 31; 35.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A/Baseline HPV6+</title>
            <description>Participants with screening CD4+ count &gt;350 cells/mm^3 (Stratum A) who were seropositive for HPV6 at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B/Baseline HPV6+</title>
            <description>Participants with screening CD4+ count &gt;200 to &lt;=350 cells/mm^3 (Stratum B) who were seropositive for HPV6 at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C/Baseline HPV6+</title>
            <description>Participants with screening CD4+ count&lt;=200 cells/mm^3 (Stratum C) who were seropositive for HPV6 at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Log10 HPV6 Antibody Titers From Baseline Among Those Seropositive for HPV6 at Baseline</title>
          <description>Change in log10 HPV6 antibody titers was calculated as log10 HPV6 antibody titers at a later timepoint (Week 28, Week 72) minus log10 HPV6 antibody titers at baseline among those seropositive for HPV6 (&gt;=20 mMU/mL) at baseline. HPV antibody titers to type 6 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (7 mMU/mL, and after assay change in December 2012, 11 mMU/mL for HPV6).</description>
          <population>All eligible participants who received at least one vaccine and were seropositive for HPV6 (HPV6+) at baseline (the number of participants analyzed) and had HPV6 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=52; n=33; n=36. Week 72: n=43; 31; 35.</population>
          <units>Log10 mMU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in HPV6 at Week 28 (n=52; 33; 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.59" upper_limit="1.54"/>
                    <measurement group_id="O2" value="1.10" lower_limit="0.61" upper_limit="1.52"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.55" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HPV6 at Week 72 (n=43; 31; 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.33" upper_limit="1.14"/>
                    <measurement group_id="O2" value="0.70" lower_limit="0.41" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.44" lower_limit="0.08" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Log10 HPV11 Antibody Titers From Baseline Among Those Seropositive for HPV11 at Baseline</title>
        <description>Change in log10 HPV11 antibody titers was calculated as log10 HPV11 antibody titers at a later timepoint (Week 28, Week 72) minus log10 HPV11 antibody titers at baseline among those seropositive for HPV11 (&gt;=16 mMU/mL) at baseline. HPV antibody titers to type 11 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (8 mMU/mL for HPV11).</description>
        <time_frame>Weeks 0, 28, 72</time_frame>
        <population>All eligible participants who received at least one vaccine and were seropositive for HPV11 (HPV11+) at baseline (the number of participants analyzed) and had HPV11 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=20; 21; 17. Week 72: n=17; 18; 19.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A/Baseline HPV11+</title>
            <description>Participants with screening CD4+ count &gt;350 cells/mm^3 (Stratum A) who were seropositive for HPV11 at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B/Baseline HPV11+</title>
            <description>Participants with screening CD4+ count &gt;200 to &lt;=350 cells/mm^3 (Stratum B) who were seropositive for HPV11 at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C/Baseline HPV11+</title>
            <description>Participants with screening CD4+ count&lt;=200 cells/mm^3 (Stratum C) who were seropositive for HPV11 at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Log10 HPV11 Antibody Titers From Baseline Among Those Seropositive for HPV11 at Baseline</title>
          <description>Change in log10 HPV11 antibody titers was calculated as log10 HPV11 antibody titers at a later timepoint (Week 28, Week 72) minus log10 HPV11 antibody titers at baseline among those seropositive for HPV11 (&gt;=16 mMU/mL) at baseline. HPV antibody titers to type 11 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (8 mMU/mL for HPV11).</description>
          <population>All eligible participants who received at least one vaccine and were seropositive for HPV11 (HPV11+) at baseline (the number of participants analyzed) and had HPV11 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=20; 21; 17. Week 72: n=17; 18; 19.</population>
          <units>Log10 mMU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in HPV11 at Week 28 (n=20; 21; 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="1.07" upper_limit="1.71"/>
                    <measurement group_id="O2" value="1.42" lower_limit="0.86" upper_limit="1.59"/>
                    <measurement group_id="O3" value="0.60" lower_limit="0.28" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HPV11 at Week 72 (n=17; 18; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.66" upper_limit="1.29"/>
                    <measurement group_id="O2" value="0.89" lower_limit="0.64" upper_limit="1.14"/>
                    <measurement group_id="O3" value="0.43" lower_limit="0.01" upper_limit="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Log10 HPV16 Antibody Titers From Baseline Among Those Seropositive for HPV16 at Baseline</title>
        <description>Change in log10 HPV16 antibody titers was calculated as log10 HPV16 antibody titers at a later timepoint (Week 28, Week 72) minus log10 HPV16 antibody titers at baseline among those seropositive for HPV16 (&gt;=20 mMU/mL) at baseline. HPV antibody titers to type 16 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (11 mMU/mL for HPV16).</description>
        <time_frame>Weeks 0, 28, 72</time_frame>
        <population>All eligible participants who received at least one vaccine and were seropositive for HPV16 (HPV16+) at baseline (the number of participants analyzed) and had HPV16 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=40; 28; 24. Week 72: n=37; 25; 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A/Baseline HPV16+</title>
            <description>Participants with screening CD4+ count &gt;350 cells/mm^3 (Stratum A) who were seropositive for HPV16 at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B/Baseline HPV16+</title>
            <description>Participants with screening CD4+ count &gt;200 to &lt;=350 cells/mm^3 (Stratum B) who were seropositive for HPV16 at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C/Baseline HPV16+</title>
            <description>Participants with screening CD4+ count&lt;=200 cells/mm^3 (Stratum C) who were seropositive for HPV16 at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Log10 HPV16 Antibody Titers From Baseline Among Those Seropositive for HPV16 at Baseline</title>
          <description>Change in log10 HPV16 antibody titers was calculated as log10 HPV16 antibody titers at a later timepoint (Week 28, Week 72) minus log10 HPV16 antibody titers at baseline among those seropositive for HPV16 (&gt;=20 mMU/mL) at baseline. HPV antibody titers to type 16 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (11 mMU/mL for HPV16).</description>
          <population>All eligible participants who received at least one vaccine and were seropositive for HPV16 (HPV16+) at baseline (the number of participants analyzed) and had HPV16 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=40; 28; 24. Week 72: n=37; 25; 24.</population>
          <units>Log10 mMU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in HPV16 at Week 28 (n=40; 28; 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="1.26" upper_limit="1.93"/>
                    <measurement group_id="O2" value="1.29" lower_limit="0.84" upper_limit="1.86"/>
                    <measurement group_id="O3" value="1.06" lower_limit="0.62" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HPV16 at Week 72 (n=37; 25; 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" lower_limit="0.79" upper_limit="1.68"/>
                    <measurement group_id="O2" value="0.97" lower_limit="0.56" upper_limit="1.59"/>
                    <measurement group_id="O3" value="0.53" lower_limit="0.17" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Log10 HPV18 Antibody Titers From Baseline Among Those Seropositive for HPV18 at Baseline</title>
        <description>Change in log10 HPV18 antibody titers was calculated as log10 HPV18 antibody titers at a later timepoint (Week 28, Week 72) minus log10 HPV18 antibody titers at baseline among those seropositive for HPV18 (&gt;=24 mMU/mL) at baseline. HPV antibody titers to type 18 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (10 mMU/mL for HPV18).</description>
        <time_frame>Weeks 0, 28, 72</time_frame>
        <population>All eligible participants who received at least one vaccine and were seropositive for HPV18 at baseline (the number of participants analyzed) and had HPV18 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=27; 11; 19. Week 72: n=25; 11; 19.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A/Baseline HPV18+</title>
            <description>Participants with screening CD4+ count &gt;350 cells/mm^3 (Stratum A) who were seropositive for HPV18 at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B/Baseline HPV18+</title>
            <description>Participants with screening CD4+ count &gt;200 to &lt;=350 cells/mm^3 (Stratum B) who were seropositive for HPV18 at baseline.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C/Baseline HPV18+</title>
            <description>Participants with screening CD4+ count&lt;=200 cells/mm^3 (Stratum C) who were seropositive for HPV18 at baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Log10 HPV18 Antibody Titers From Baseline Among Those Seropositive for HPV18 at Baseline</title>
          <description>Change in log10 HPV18 antibody titers was calculated as log10 HPV18 antibody titers at a later timepoint (Week 28, Week 72) minus log10 HPV18 antibody titers at baseline among those seropositive for HPV18 (&gt;=24 mMU/mL) at baseline. HPV antibody titers to type 18 were measured centrally using the competitive Luminex ImmunoAssay (HPV-4, cLIA) on stored serum. The results below the lower limit of detection (LLD) were assigned the values of half the LLD (10 mMU/mL for HPV18).</description>
          <population>All eligible participants who received at least one vaccine and were seropositive for HPV18 at baseline (the number of participants analyzed) and had HPV18 titer available at the respective follow-up week. Strata A; B; C. Week 28: n=27; 11; 19. Week 72: n=25; 11; 19.</population>
          <units>Log10 mMU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in HPV18 at Week 28 (n=27; 11; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.48" upper_limit="1.51"/>
                    <measurement group_id="O2" value="0.89" lower_limit="0.50" upper_limit="1.53"/>
                    <measurement group_id="O3" value="0.85" lower_limit="0.04" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HPV18 at Week 72 (n=25; 11; 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" lower_limit="0.17" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.20" lower_limit="-0.08" upper_limit="0.96"/>
                    <measurement group_id="O3" value="0.14" lower_limit="0.02" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Signs and Symptoms of Grade 3 or Higher</title>
        <description>Number of participants who experienced a sign or symptom of Grade 3 or higher at any time after baseline while on study. Grading of signs and symptoms was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004.</description>
        <time_frame>From baseline to up to Week 72</time_frame>
        <population>All eligible participants who received at least one vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A</title>
            <description>Participants with screening CD4 count &gt;350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B</title>
            <description>Participants with screening CD4 count &gt;200 to &lt;=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C</title>
            <description>Participants with screening CD4 count &lt;=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Signs and Symptoms of Grade 3 or Higher</title>
          <description>Number of participants who experienced a sign or symptom of Grade 3 or higher at any time after baseline while on study. Grading of signs and symptoms was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004.</description>
          <population>All eligible participants who received at least one vaccine.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Abnormalities of Grade 3 or Higher</title>
        <description>Number of participants who experienced a laboratory abnormality of Grade 3 or higher at any time after baseline while on study. Grading of laboratory abnormalities was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004.</description>
        <time_frame>From baseline to up to Week 72</time_frame>
        <population>All eligible participants who received at least one vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A</title>
            <description>Participants with screening CD4 count &gt;350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B</title>
            <description>Participants with screening CD4 count &gt;200 to &lt;=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C</title>
            <description>Participants with screening CD4 count &lt;=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities of Grade 3 or Higher</title>
          <description>Number of participants who experienced a laboratory abnormality of Grade 3 or higher at any time after baseline while on study. Grading of laboratory abnormalities was according to Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004.</description>
          <population>All eligible participants who received at least one vaccine.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Log10 HIV Viral Load (VL) From Baseline</title>
        <description>A blood sample was drawn for local testing to determine the HIV VL. Change in log10 HIV VL was calculated as log10 HIV VL at a later time point (Weeks 4, 12, 28, 52 and 72) minus log10 HIV VL at baseline.</description>
        <time_frame>Weeks 0, 4, 12, 28, 52, and 72</time_frame>
        <population>N=315 eligible participants who initiated intervention and had HIV VL available at Week 0 and the respective follow-up week. Strata A; B; C. Week 4: n=123; 89; 88. Week 12: n=118; 89; 90. Week 28: n=118; 91; 87. Week 52: n=109; 85; 82. Week 72: n=105; 81; 83.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A</title>
            <description>Participants with screening CD4 count &gt;350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B</title>
            <description>Participants with screening CD4 count &gt;200 to &lt;=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C</title>
            <description>Participants with screening CD4 count &lt;=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Log10 HIV Viral Load (VL) From Baseline</title>
          <description>A blood sample was drawn for local testing to determine the HIV VL. Change in log10 HIV VL was calculated as log10 HIV VL at a later time point (Weeks 4, 12, 28, 52 and 72) minus log10 HIV VL at baseline.</description>
          <population>N=315 eligible participants who initiated intervention and had HIV VL available at Week 0 and the respective follow-up week. Strata A; B; C. Week 4: n=123; 89; 88. Week 12: n=118; 89; 90. Week 28: n=118; 91; 87. Week 52: n=109; 85; 82. Week 72: n=105; 81; 83.</population>
          <units>Log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in log10 HIV VL at Week 4 (n=123; 89; 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.18" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.06" upper_limit="0.11"/>
                    <measurement group_id="O3" value="0" lower_limit="-0.15" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in log10 HIV VL at Week 12 (n=118; 89; 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.27" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.21" upper_limit="0.09"/>
                    <measurement group_id="O3" value="0" lower_limit="-0.45" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in log10 HIV VL at Week 28 (n=118; 91; 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.43" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.63" upper_limit="0.12"/>
                    <measurement group_id="O3" value="0" lower_limit="-0.46" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in log10 HIV VL at Week 52 (n=109; 85; 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.53" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0" lower_limit="-1.11" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="-1.28" upper_limit="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in log10 HIV VL at Week 72 (n=105; 81; 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.59" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-1.03" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="-1.93" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4 Cell Count From Baseline</title>
        <description>A blood sample was drawn for local testing to determine the CD4 cell count. Change in CD4 cell count was calculated as CD4 cell count at a later time point (Weeks 4, 8, 12, 24, 28, 52 and 72) minus CD4 cell count at baseline.</description>
        <time_frame>Weeks 0, 4, 8, 12, 24, 28, 52 and 72</time_frame>
        <population>N=315 eligible participants who initiated intervention and had data available at Week 0 and the respective follow-up week. Strata A; B; C. Week 4: n=122; 92; 88. Week 8: n=119; 92; 90. Week 12: n=115; 87; 90. Week 24: n=117; 85; 88. Week 28: n=114; 89; 87. Week 52: n=108; 85; 87. Week 72: 105; 85; 88.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A</title>
            <description>Participants with screening CD4 count &gt;350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O2">
            <title>Stratum B</title>
            <description>Participants with screening CD4 count &gt;200 to &lt;=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
          <group group_id="O3">
            <title>Stratum C</title>
            <description>Participants with screening CD4 count &lt;=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Cell Count From Baseline</title>
          <description>A blood sample was drawn for local testing to determine the CD4 cell count. Change in CD4 cell count was calculated as CD4 cell count at a later time point (Weeks 4, 8, 12, 24, 28, 52 and 72) minus CD4 cell count at baseline.</description>
          <population>N=315 eligible participants who initiated intervention and had data available at Week 0 and the respective follow-up week. Strata A; B; C. Week 4: n=122; 92; 88. Week 8: n=119; 92; 90. Week 12: n=115; 87; 90. Week 24: n=117; 85; 88. Week 28: n=114; 89; 87. Week 52: n=108; 85; 87. Week 72: 105; 85; 88.</population>
          <units>Cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in CD4 count at Week 4 (n=122; 92; 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="-52" upper_limit="94"/>
                    <measurement group_id="O2" value="-3" lower_limit="-45" upper_limit="29"/>
                    <measurement group_id="O3" value="5" lower_limit="-13" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count at Week 8 (n=119; 92; 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="-66" upper_limit="118"/>
                    <measurement group_id="O2" value="-8" lower_limit="-59" upper_limit="58"/>
                    <measurement group_id="O3" value="13" lower_limit="-15" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count at Week 12 (n=115; 87; 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="-99" upper_limit="104"/>
                    <measurement group_id="O2" value="-3" lower_limit="-42" upper_limit="63"/>
                    <measurement group_id="O3" value="13" lower_limit="-19" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count at Week 24 (n=117; 85; 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="-66" upper_limit="92"/>
                    <measurement group_id="O2" value="27" lower_limit="-50" upper_limit="77"/>
                    <measurement group_id="O3" value="12" lower_limit="-31" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count at Week 28 (n=114; 89; 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="-60" upper_limit="113"/>
                    <measurement group_id="O2" value="37" lower_limit="-49" upper_limit="104"/>
                    <measurement group_id="O3" value="17" lower_limit="-25" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count at Week 52 (n=108; 85; 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="-119" upper_limit="117"/>
                    <measurement group_id="O2" value="49" lower_limit="-32" upper_limit="151"/>
                    <measurement group_id="O3" value="40" lower_limit="-28" upper_limit="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count at Week 72 (n=105; 85; 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="-91" upper_limit="93"/>
                    <measurement group_id="O2" value="65" lower_limit="6" upper_limit="146"/>
                    <measurement group_id="O3" value="46" lower_limit="-26" upper_limit="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to up to Week 72</time_frame>
      <desc>The protocol required reporting of signs and symptoms and laboratory abnormalities of &gt;=Grade 2 and all grades of fever. The DAIDS Adverse Event (AE) Grading Table, Version 1.0, December 2004 (Clarification, August 2009) was used for grading of AEs. Expedited adverse event reporting followed Version 2.0 of the DAIDS Expedited Adverse Event Manual.</desc>
      <group_list>
        <group group_id="E1">
          <title>Stratum A</title>
          <description>Participants with screening CD4 count &gt;350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
        </group>
        <group group_id="E2">
          <title>Stratum B</title>
          <description>Participants with screening CD4 count &gt;200 to &lt;=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
        </group>
        <group group_id="E3">
          <title>Stratum C</title>
          <description>Participants with screening CD4 count &lt;=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Leukoplakia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis trichomonal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ACTG Clinicaltrials.gov Coordinator</name_or_title>
      <organization>ACTG Network Coordinating Center, Social and Scientific Systems, Inc.</organization>
      <phone>(301)-628-3313</phone>
      <email>ACTGCT.Gov@s-3.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

